Is Bal Pharma the Best Stock in Its Sector? A Look at the Numbers

Is Bal Pharma the best stock in its sector? The stock trades on the NSE at Rs 108 as of 24 September 2026, within its 52-week range of Rs 60.00 to Rs 124.60. Bal Pharma Ltd manufactures generic pharmaceutical formulations for domestic and export markets.

Bal Pharma sits in the Healthcare sector, and its 7.64% ROE and 23.72x P/E give a starting point for judging where it stands against comparable listed names. The rest of this article compares those numbers against verified peers and the sector's Industry P/E benchmark.

Also read – Is Abbott India the Best Stock in Its Sector? A Look at the Numbers

Click Here – Get Free Investment Predictions

About Bal Pharma

Bal Pharma Ltd manufactures generic pharmaceutical formulations for domestic and export markets. It manufactures generic pharmaceutical formulations for domestic and export markets, operating at a considerably smaller scale than the larger formulation and API makers it is compared against here. At a market capitalisation of Rs 172 Cr, it is tracked as part of the Healthcare sector on Univest.

Is Bal Pharma the Best Stock in Its Sector?

Bal Pharma makes its case as the best stock in its sector primarily on valuation relative to its Industry P/E, combining a 7.64% ROE with a 23.72x P/E against the sector's 38.33x Industry P/E. Bal Pharma's 23.72x P/E is well below the 38.33x Industry P/E, though its 7.64% ROE trails Alpa Laboratories and Anuh Pharma in this comparison, and its higher leverage is a factor worth weighing against the valuation discount.

Metric	Bal Pharma
CMP (NSE)	Rs 108.28
52-Week High / Low	Rs 124.60 / Rs 60.00
Market Cap	Rs 172 Cr
P/E (TTM) vs Industry P/E	23.72x vs 38.33x
P/B	2.09
ROE	7.64%
EPS (TTM)	Rs 4.55
Dividend Yield	1.11%
Debt to Equity	1.94

Compare Bal Pharma Against Other Healthcare Sector Stocks

How Bal Pharma Compares Against Its Healthcare Sector Peers

The table below sets Bal Pharma against 2 other Healthcare sector names, using the same live data source for every company. A peer average row is included for P/E, ROE and debt to equity, calculated across the 2 peer companies.

Company	Market Cap (Rs Cr)	P/E	ROE	Debt to Equity
Bal Pharma	172	23.72	7.64%	1.94
Alpa Laboratories	128	31.43	8.06%	0.01
Anuh Pharma	942	21.32	11.65%	0.00
Peer average (2 companies)	-	26.38	9.86%	0.01

Against this peer set, Bal Pharma's 7.64% ROE is below the 9.86% peer average, and its P/E of 23.72x runs below the peer average of 26.38x. Bal Pharma's 23.72x P/E is well below the 38.33x Industry P/E, though its 7.64% ROE trails Alpa Laboratories and Anuh Pharma in this comparison, and its higher leverage is a factor worth weighing against the valuation discount.

What Makes Bal Pharma Worth Watching in Healthcare

• Well below Industry P/E: A 23.72x P/E against a 38.33x Industry P/E is a discount for a generic formulations manufacturer.
• Solid ROE: A 7.64% ROE is a reasonable figure for a smaller-scale pharma formulations business.
• Higher leverage for a smaller pharma company: A debt to equity ratio of 1.94 is on the higher side, worth watching alongside its smaller operating scale.

Bal Pharma Valuation: Is It Justified?

Bal Pharma's 23.72x P/E is well below the 38.33x Industry P/E, though its 7.64% ROE trails Alpa Laboratories and Anuh Pharma in this comparison, and its higher leverage is a factor worth weighing against the valuation discount. As with any single stock, investors should weigh this against their own valuation discipline and risk appetite rather than the sector label alone.

Also read – Is AWL Agri Business the Best Stock in Its Sector? A Look at the Numbers

Download the Univest iOS App or Univest Android App to track Bal Pharma and other Healthcare sector stocks.

How to Track Bal Pharma Before You Invest

Before deciding whether Bal Pharma deserves its label as the best stock in its sector for your own portfolio, compare it directly against Healthcare sector peers using the steps below.

1. Open the Univest Screener and search for Bal Pharma to view live price, valuation ratios, and peer comparisons within the Healthcare sector.
2. Compare its P/E, P/B, and ROE against other Healthcare sector stocks before deciding if the current valuation fits your strategy.
3. Set a price alert around key support and resistance zones using the Univest app so you are notified of meaningful moves.
4. Open a broking account on Univest if you decide to add the stock, and size the position based on your own risk appetite and portfolio allocation.

Conclusion

Bal Pharma earns a place in the best stock in its sector conversation on the strength of a 7.64% ROE and a P/E of 23.72x against a 38.33x Industry P/E, with named peer comparisons in this article backing up that picture. As with any individual stock decision, this analysis is educational and investors should do their own research or consult a SEBI-registered advisor before investing.

Is Bal Pharma the best stock in its sector?

Ans. Bal Pharma has a 7.64% ROE and trades at 23.72x P/E against a 38.33x Industry P/E, and compares below the peer average ROE of 9.86% in this article's named comparison, so the answer depends on what an investor is prioritising.

What is the current share price of Bal Pharma?

Ans. Bal Pharma was trading at Rs 108.28 on the NSE as of 24 September 2026, within its 52-week range of Rs 60.00 to Rs 124.60.

What sector does Bal Pharma belong to?

Ans. Bal Pharma is classified under the Healthcare sector on Univest.

How does Bal Pharma compare to its sector peers on P/E?

Ans. Bal Pharma's P/E of 23.72x is below the 26.38x average of the 2 named peers compared in this article.

What is Bal Pharma's return on equity?

Ans. Bal Pharma reported a return on equity of 7.64%, which is below the 9.86% average of its named peers in this comparison.

Should I invest in Bal Pharma based on its sector position?

Ans. Bal Pharma's sector position and metrics make it worth researching further, but any investment decision should factor in your own risk appetite, its valuation relative to peers, and independent research or advice from a SEBI-registered advisor.